Xenon Pharmaceuticals Inc. (XENE): who owns it and who trades it
As of Nov 16, 2026, XENE insiders reported 26 open-market sales worth $22M and 2 purchases worth $1.7M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Ian Mortimer (CEO), with $20.3M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Xenon Pharmaceuticals
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns XENE
314 funds and institutions reported XENE shares worth $6.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 10.0%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 9.65M | 9.98% | $582M | -11% |
| BlackRock, Inc. | 7.52M | 7.78% | $454M | +33% |
| Avoro Capital Advisors LLC | 5.78M | 5.98% | $349M | No change |
| Polar Capital Holdings Plc | 4.57M | 4.73% | $276M | +4% |
| Driehaus Capital Management LLC | 4.42M | 4.57% | $267M | -2% |
| Jupiter Topco LLC | 4.19M | 4.33% | $253M | – |
| T. Rowe Price Associates | 3.25M | 3.36% | $196M | +144% |
| JPMorgan Chase & Co | 2.62M | 2.71% | $157M | – |
| Capital International Investors | 2.36M | 2.44% | $143M | -12% |
| T. Rowe Price Investment Management, Inc. | 2.17M | 2.24% | $131M | +128% |
| State Street Corp | 1.97M | 2.04% | $119M | +14% |
| Two Sigma Investments, LP | 1.64M | 1.70% | $99.2M | +171% |
| Deerfield Management Company, L.P. | 1.62M | 1.67% | $97.5M | No change |
| Affinity Asset Advisors, LLC | 1.59M | 1.65% | $96.3M | -5% |
| Alliancebernstein L.P. | 1.56M | 1.62% | $90.8M | +11% |
| Westfield Capital Management Co LP | 1.51M | 1.56% | $91M | +8% |
| Franklin Resources Inc | 1.44M | 1.49% | $86.8M | +12% |
| Wellington Management Group LLP | 1.43M | 1.47% | $86M | -70% |
| Citadel Advisors LLC | 1.40M | 1.45% | $84.6M | -47% |
| Geode Capital Management, LLC | 1.37M | 1.42% | $82.7M | +25% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, XENE insiders reported $1.7M of open-market purchases and $22M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Thomas Patrick Kelly | CFO | Purchase | 15,000 | $37.32 | $560K | Form 4 |
| Sep 30, 2026 | Ian Mortimer | CEO | Purchase | 30,000 | $37.38 | $1.1M | Form 4 |
| Aug 28, 2026 | Christopher John Kenney | Chief Medical Officer | Sale | 6,368 | $60.17 | $383K | Form 4 |
| Aug 28, 2026 | Christopher John Kenney | Chief Medical Officer | Sale | 700 | $60.98 | $42.7K | Form 4 |
| Aug 11, 2026 | Steven Gannon | Director | Sale | 10,000 | $64.06 | $641K | Form 4 |
| Jun 5, 2026 | Gary Patou | Director | Sale | 1,322 | $53.14 | $70.3K | Form 4 |
| Jun 5, 2026 | Gillian Cannon | Director | Sale | 1,190 | $53.14 | $63.2K | Form 4 |
| Mar 13, 2026 | Christopher John Kenney | Chief Medical Officer | Sale | 1,410 | $55.23 | $77.9K | Form 4 |
| Mar 13, 2026 | Andrea DiFabio | Chief Legal Officer | Sale | 1,342 | $55.23 | $74.1K | Form 4 |
| Mar 13, 2026 | Ian Mortimer | CEO | Sale | 7,308 | $55.23 | $404K | Form 4 |
| Mar 10, 2026 | Christopher John Kenney | Chief Medical Officer | Sale | 2,771 | $60.11 | $167K | Form 4 |
| Mar 10, 2026 | Andrea DiFabio | Chief Legal Officer | Sale | 2,607 | $60.11 | $157K | Form 4 |
| Mar 10, 2026 | Ian Mortimer | CEO | Sale | 11,269 | $60.11 | $677K | Form 4 |
| Mar 9, 2026 | Ian Mortimer | CEO | Sale | 21,791 | $58.81 | $1.3M | Form 4 |
| Mar 9, 2026 | Ian Mortimer | CEO | Sale | 31,694 | $59.88 | $1.9M | Form 4 |
| Mar 9, 2026 | Ian Mortimer | CEO | Sale | 21,515 | $60.49 | $1.3M | Form 4 |
| Mar 9, 2026 | Ian Mortimer | CEO | Sale | 12,479 | $59.50 | $743K | Form 4 |
| Mar 9, 2026 | Ian Mortimer | CEO | Sale | 10,072 | $60.47 | $609K | Form 4 |
| Mar 9, 2026 | Ian Mortimer | CEO | Sale | 2,449 | $61.26 | $150K | Form 4 |
| Mar 9, 2026 | Ian Mortimer | CEO | Sale | 43,348 | $59.26 | $2.6M | Form 4 |
| Mar 9, 2026 | Ian Mortimer | CEO | Sale | 61,652 | $60.08 | $3.7M | Form 4 |
| Mar 9, 2026 | Ian Mortimer | CEO | Sale | 65,000 | $62.06 | $4M | Form 4 |
| Jan 2, 2026 | Ian Mortimer | CEO | Sale | 37,938 | $44.40 | $1.7M | Form 4 |
| Jan 2, 2026 | Ian Mortimer | CEO | Sale | 2,062 | $44.93 | $92.6K | Form 4 |
| Dec 8, 2025 | Ian Mortimer | CEO | Sale | 2,010 | $46.32 | $93.1K | Form 4 |
| Dec 8, 2025 | Ian Mortimer | CEO | Sale | 8,820 | $45.59 | $402K | Form 4 |
| Dec 5, 2025 | Ian Mortimer | CEO | Sale | 14,375 | $45.03 | $647K | Form 4 |
| Nov 28, 2025 | Ian Mortimer | CEO | Sale | 97 | $45.01 | $4.4K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Ian Mortimer | PRESIDENT & CEO, Director | $1.1M | $20.3M | Sep 30, 2026 |
| Christopher John Kenney | Chief Medical Officer | – | $670K | Aug 28, 2026 |
| Steven Gannon | Director | – | $641K | Aug 11, 2026 |
| Thomas Patrick Kelly | Chief Financial Officer | $560K | – | Sep 30, 2026 |
| Andrea DiFabio | Chief Legal Officer | – | $231K | Mar 13, 2026 |
| Gary Patou | Director | – | $70.3K | Jun 5, 2026 |
| Gillian Cannon | Director | – | $63.2K | Jun 5, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
XENE short interest
Moderate short interest. 7.6% of XENE shares are sold short: about 1 share in 13. Over the last 12 reports the number of shares short went up 92%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 7.36M XENE shares were sold short, 7.6% of the shares outstanding, up 0.2% from the report before. At the average daily volume of 1.16M shares, buying them all back would take about 6.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 7.36M | 7.60% | +0% | 1.16M | 6.4 |
| Oct 15, 2026 | 7.35M | 7.59% | +22% | 1.86M | 4.0 |
| Sep 30, 2026 | 6.04M | 6.24% | -6% | 3.83M | 1.6 |
| Sep 15, 2026 | 6.44M | 6.66% | +2% | 527,345 | 12.2 |
| Aug 31, 2026 | 6.34M | 6.55% | +12% | 698,275 | 9.1 |
| Aug 14, 2026 | 5.67M | 5.85% | +5% | 618,635 | 9.2 |
| Jul 31, 2026 | 5.38M | 5.57% | -15% | 734,532 | 7.3 |
| Jul 15, 2026 | 6.34M | 6.56% | +1% | 1.78M | 3.6 |
| Jun 30, 2026 | 6.26M | 6.47% | +42% | 2.11M | 3.0 |
| Jun 15, 2026 | 4.41M | 4.56% | +9% | 1.38M | 3.2 |
| May 29, 2026 | 4.04M | 4.18% | +6% | 1.38M | 2.9 |
| May 15, 2026 | 3.83M | 3.97% | -8% | 947,846 | 4.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Xenon Pharmaceuticals company events
Xenon Pharmaceuticals filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 3, 2026LeadershipAs discussed in Item 5.07 below, upon the recommendation of the Board of Directors of Xenon Pharmaceuticals Inc., the shareholders of the Company, at the Company's annual meeting of shareholders held on June 2, 2026, approved the Xenon Pharmaceuticals Inc. 2026 Equity Incentive Plan, to replace the… Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 13, 2026LeadershipXenon Pharmaceuticals Inc. amended and restated the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan (as amended and restated, the “2025 Inducement Plan”) to increase the maximum number of shares of its common stock reserved for issuance under the 2025 Inducement Plan from… Filing
- Mar 13, 2026AnnouncementXenon Pharmaceuticals Inc. announced the meeting, record date and certain other information relating to its 2026 annual meeting of shareholders pursuant to a filing submitted to the System for Electronic Document Analysis and Retrieval in Canada. Filing
- Mar 12, 2026AgreementThe information set forth below in Item 8.01 of this report with respect to the pre-funded warrants issued and sold in the offering (described below) is incorporated by reference into this Item 1.01. Filing
- Mar 9, 2026AnnouncementShared information with investors. Filing
- Feb 27, 2026AnnouncementXenon Pharmaceuticals Inc. filed a prospectus supplement with the Securities and Exchange Commission to register $400 million of common shares, without par value issuable pursuant to the at-the-market equity offering sales agreement, dated August 6, 2020, as amended on March 1, 2022, by and among… Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Dec 1, 2025LeadershipXenon Pharmaceuticals Inc. amended and restated the Company’s 2025 Inducement Equity Incentive Plan (as amended and restated, the “2025 Inducement Plan”) to increase the maximum number of shares of its common stock reserved for issuance under the 2025 Inducement Plan from 775,000 shares to 900,000… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Xenon Pharmaceuticals financials
Famous investors that hold XENE
4 of the 50 well-known investors we track reported holding XENE in their latest 13F filing. The largest position is Steve Cohen's, worth $44.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.19M | $44.3M | 0.1% | +813% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 322,498 | $12M | 0.0% | -77% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 277,200 | $10.3M | 0.0% | +48% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 16,483 | $613K | 0.0% | -97% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named XENE in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Polar Capital Holdings Plc | 13G | 5.2% |
| Nov 16, 2026 | Polar Capital Holdings Plc | 13G | 5.2% |
| Nov 6, 2026 | T. Rowe Price Investment Management, Inc. | 13G | 8.2% |
| Nov 6, 2026 | T. Rowe Price Investment Management, Inc. | 13G | 8.2% |
| Nov 6, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 10.3% |
| Nov 6, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 10.3% |
| Nov 5, 2026 | FMR LLC | 13G/A | 11.5% |
| Nov 5, 2026 | FMR LLC | 13G/A | 11.5% |
Questions about Xenon Pharmaceuticals Inc. (XENE) stock
Who owns the most XENE stock?
The largest reported owner of Xenon Pharmaceuticals Inc. (XENE) is FMR LLC (Fidelity), with 10.0% of the company. In total, 314 funds and institutions reported holding XENE at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are XENE insiders buying or selling?
In the last 12 months, XENE insiders reported 2 open-market purchases worth $1.7M and 26 sales worth $22M. The latest trade was on Sep 30, 2026. See every trade.
What is the short interest in XENE?
As of Oct 30, 2026, 7.36M XENE shares were sold short, 7.6% of the shares outstanding, up 0.2% from the report before. At the average daily volume of 1.16M shares, buying them all back would take about 6.4 trading days (days to cover). See the history.
Which famous investors hold XENE?
4 of the 50 well-known investors we track reported XENE in their latest 13F filing, including Steve Cohen, Ken Griffin, Jim Simons. The largest position is worth $44.3M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.